Soligenix Inc (SNGX) Stock Price, Quote & News

Company Profile

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology th...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 538 8200

Fax: 609 452 6467

Website: www.soligenix.com

Address:

29 Emmons Drive, Suite B-10, Princeton, United States

Farhas80 Aug. 26 at 2:25 PM

$SNGX CEO probably drank and on a hibernation mode. It’s been long wait for any news.

0 · Reply

BmoreBoy89 Aug. 25 at 6:45 PM

$SNGX CEPI 100 Day Review. https://cepi.net/100-days-bundibugyo-emergency-unprecedented-speed-still-not-enough

0 · Reply

Farhas80 Aug. 25 at 2:12 PM

$SNGX silence before explosions. We need update on Ebola to move this over $1.

0 · Reply

GreedyGopher Aug. 24 at 4:03 PM

$SNGX whens reverse split#5 happening.???...and then the mass dilution? This company has never brought anything to market and never will....the next pump will bring a new wave of bagholders.. Schaber thanks you.......come again!

0 · Reply

ASHarris81 Aug. 24 at 11:17 AM

$SNGX very interesting Premarket

0 · Reply

splendor Aug. 24 at 9:24 AM

$SNGX somone know something about the next days Look the last volume. Big news coming soon,

2 · Reply

Spicy_Weeklies Aug. 23 at 2:49 PM

$CING The risk‑on macro shift we might be seeing play out implies falling yields, expanding liquidity, and surging speculative inflow. This tends to raise investor appetite for high‑beta small‑cap names, which strengthens baseline demand for CING even before catalysts. With biotech multiples stabilizing and recent Russell inclusion providing steady mechanical buying, not to mention such a low float, CING may benefit from a more supportive trading environment that reduces downside volatility and increases the likelihood of upward drift. The floor will start rising naturally. If CING delivers clean regulatory progress into this backdrop, the macro tailwind will amplify the magnitude of any positive move, making each milestone more impactful than it would be in a risk‑off market. $COIN $MARA $SLS $SNGX

2 · Reply

ASHarris81 Aug. 21 at 7:57 PM

$SNGX something is up...

1 · Reply

Farhas80 Aug. 20 at 12:30 PM

$SNGX 200% - 300% up day coming with good news. Best time to add or avg down.

1 · Reply

splendor Aug. 20 at 8:39 AM

$SNGX CEPI is funding today $4.17M to test if legacy Ebola vaccines offer cross-protection against Bundibugyo. With existing shots triggering a 6–8x weaker antibody response, current options fall short. This directly underscores $SNGX: Soligenix’s platform has already demonstrated robust cross-neutralization against both Zaire and Sudan strains. Since their formulation is already developed, researchers don't need to start from scratch—$SNGX's existing sera can be tested immediately in-vitro against Bundibugyo, potentially offering a vastly superior and ready-to-test cross-reactive solution. With $SNGX already on CEPI’s radar for immediate countermeasures, this catalyst could reprice the stock rapidly before the market catches on. https://cepi.net/new-studies-test-whether-existing-ebola-vaccines-can-generate-immune-responses-bundibugyo

1 · Reply

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

Aug 7, 2026, 7:00 AM EDT - 19 days ago

Soligenix Quarterly report: Q2 2026

Aug 3, 2026, 8:00 AM EDT - 23 days ago

Soligenix Proxy statement: Proxy filing

Aug 3, 2026, 8:00 AM EDT - 23 days ago

Soligenix Proxy statement: Proxy filing

Jul 23, 2026, 8:00 AM EDT - 4 weeks ago

Soligenix Proxy statement: Proxy filing

Jul 21, 2026, 8:00 AM EDT - 5 weeks ago

Soligenix Proxy statement: Proxy filing

2026-06-08T11:45:52.000Z - 2 months ago

Soligenix to apply for vaccine development funding for Bundibugyo Ebola vaccine

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

May 26, 2026, 7:30 AM EDT - 3 months ago

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

2026-05-08T12:43:19.000Z - 3 months ago

Soligenix reports Q1 EPS (28c) vs. (97c) last year

May 8, 2026, 7:30 AM EDT - 3 months ago

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 3 months ago

Soligenix Earnings release: Q1 2026

2026-05-04T11:16:01.000Z - 4 months ago

Soligenix price target lowered to $1.50 from $10 at Alliance Global

2026-04-28T12:08:02.000Z - 4 months ago

Soligenix announces interim results of Phase 3 trial of HyBryte in lymphoma

Apr 28, 2026, 7:30 AM EDT - 4 months ago

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Apr 8, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

2026-04-02T12:03:59.000Z - 5 months ago

Soligenix’s HyBryte shows efficacy in T-cell lymphoma published trial

Apr 2, 2026, 7:30 AM EDT - 5 months ago

Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

Mar 31, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Soligenix Annual report: Q4 2025

2026-03-26T11:36:24.000Z - 5 months ago

Soligenix’s SGX945 granted European Orphan Drug Designation in Behcet’s Disease

Mar 26, 2026, 7:30 AM EDT - 5 months ago

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

Mar 26, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

Mar 23, 2026, 7:30 AM EDT - 5 months ago

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Mar 19, 2026, 8:00 AM EDT - 5 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Dr. Christopher Schaber, CEO of Soligenix Inc.

2026-03-19T11:36:43.000Z - 5 months ago

Soligenix announces HyBryte clinical summary published

Mar 19, 2026, 7:30 AM EDT - 5 months ago

Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Mar 17, 2026, 7:00 AM EDT - 5 months ago

Soligenix Slides: Corporate presentation

2026-03-10T11:42:32.000Z - 6 months ago

Soligenix says SGX945 granted PIM designation in UK by MHRA

Mar 10, 2026, 7:30 AM EDT - 6 months ago

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

2026-02-26T13:00:59.000Z - 6 months ago

Soligenix receives positive opinion from EMA for OOD request for dusquetide

Feb 26, 2026, 7:30 AM EST - 6 months ago

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

Feb 24, 2026, 7:30 AM EST - 6 months ago

Soligenix to Present at BIO Investment & Growth Summit

Feb 12, 2026, 7:30 AM EST - 6 months ago

Soligenix Details Recent Progress and Upcoming Milestones

2025-12-18T12:41:21.000Z - 8 months ago

Soligenix’s SGX945 in Behcet’s Disease published in Rheumatology (Oxford)

Dec 18, 2025, 7:30 AM EST - 8 months ago

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

2025-12-17T12:36:34.000Z - 9 months ago

Soligenix announces results from Phase 2a trial of SGX302

Dec 17, 2025, 7:30 AM EST - 9 months ago

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Dec 3, 2025, 8:30 AM EST - 9 months ago

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

2025-11-19T12:35:43.000Z - 10 months ago

Soligenix completes enrollment of patients for Phase 3 study evaluating HyBryte

Nov 19, 2025, 7:30 AM EST - 10 months ago

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Nov 7, 2025, 7:30 AM EST - 10 months ago

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

Nov 7, 2025, 7:00 AM EST - 10 months ago

Soligenix Quarterly report: Q3 2025

Oct 14, 2025, 7:30 AM EDT - 11 months ago

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

2025-10-07T11:35:32.000Z - 11 months ago

Soligenix’s HyBryte achieves safety milestone in Phase 3 T-cell lymphoma trial

Oct 7, 2025, 7:30 AM EDT - 11 months ago

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

2025-09-30T11:35:29.000Z - 11 months ago

Soligenix expands European Medical Advisory Board for CTCL

Sep 30, 2025, 7:30 AM EDT - 11 months ago

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Sep 29, 2025, 4:05 PM EDT - 11 months ago

Soligenix Announces Closing of $7.5 Million Public Offering

Sep 26, 2025, 6:33 AM EDT - 11 months ago

Soligenix Announces Pricing of $7.5 Million Public Offering

Sep 23, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

2025-09-19T21:05:11.000Z - 1 year ago

Soligenix files to sell 2.91M shares of common stock, 2.91M warrants

Sep 19, 2025, 8:00 AM EDT - 1 year ago

Soligenix Registration statement: Registration Filing

Sep 19, 2025, 7:00 AM EDT - 1 year ago

Soligenix Slides: Corporate Presentation

2025-09-04T11:35:46.000Z - 1 year ago

Soligenix’s ThermoVax platform shows efficacy in vaccine stability

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Sep 2, 2025, 7:30 AM EDT - 1 year ago

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-18T11:35:27.000Z - 1 year ago

Soligenix’s dusquetide granted Orphan Drug Designation in Behcet’s Disease

Aug 18, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

2025-08-13T22:00:32.000Z - 1 year ago

Soligenix receives FDA orphan designation for dusquetide

Aug 8, 2025, 8:30 AM EDT - 1 year ago

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

Jul 8, 2025, 7:30 AM EDT - 1 year ago

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones

Jul 1, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions

Jun 6, 2025, 9:37 AM EDT - 1 year ago

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

May 9, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Quarterly report: Q1 2025

May 8, 2025, 7:00 PM EDT - 1 year ago

Soligenix Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Soligenix Proxy statement: Proxy Filing

Apr 14, 2025, 7:30 AM EDT - 1 year ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

Mar 25, 2025, 8:30 AM EDT - 1 year ago

IBN Initiates Coverage of Soligenix Inc.

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Mar 21, 2025, 7:30 AM EDT - 1 year ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Annual report: Q4 2024

Mar 20, 2025, 8:00 PM EDT - 1 year ago

Soligenix Earnings release: Q4 2024

Mar 6, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Feb 4, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at BIO CEO & Investor Conference

Jan 16, 2025, 7:30 AM EST - 1 year ago

Soligenix to Present at Upcoming Investor Conferences

Jan 14, 2025, 7:30 AM EST - 1 year ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Dec 16, 2024, 7:30 AM EST - 1 year ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Dec 2, 2024, 7:30 AM EST - 1 year ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Nov 19, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Nov 15, 2024, 7:30 AM EST - 1 year ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Nov 14, 2024, 7:15 AM EST - 1 year ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Nov 8, 2024, 7:30 AM EST - 1 year ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Farhas80 Aug. 26 at 2:25 PM

$SNGX CEO probably drank and on a hibernation mode. It’s been long wait for any news.

0 · Reply

BmoreBoy89 Aug. 25 at 6:45 PM

$SNGX CEPI 100 Day Review. https://cepi.net/100-days-bundibugyo-emergency-unprecedented-speed-still-not-enough

0 · Reply

Farhas80 Aug. 25 at 2:12 PM

$SNGX silence before explosions. We need update on Ebola to move this over $1.

0 · Reply

GreedyGopher Aug. 24 at 4:03 PM

0 · Reply

ASHarris81 Aug. 24 at 11:17 AM

$SNGX very interesting Premarket

0 · Reply

splendor Aug. 24 at 9:24 AM

$SNGX somone know something about the next days Look the last volume. Big news coming soon,

2 · Reply

Spicy_Weeklies Aug. 23 at 2:49 PM

2 · Reply

ASHarris81 Aug. 21 at 7:57 PM

$SNGX something is up...

1 · Reply

Farhas80 Aug. 20 at 12:30 PM

$SNGX 200% - 300% up day coming with good news. Best time to add or avg down.

1 · Reply

splendor Aug. 20 at 8:39 AM

1 · Reply

splendor Aug. 20 at 8:21 AM

$SNGX feel like a big news coming soon

0 · Reply

DrLotto Aug. 19 at 4:33 PM

$SNGX Lottery any time soon

1 · Reply

BmoreBoy89 Aug. 19 at 2:08 PM

$SNGX $MRNA Whoa!

0 · Reply

splendor Aug. 19 at 11:03 AM

$MRNA wow that looks amazing Can imagin whats will happen to $SNGX when the cepi fund coming

1 · Reply

splendor Aug. 19 at 10:57 AM

$MRNA wow Come to $SNGX A big find will coming soon Vaccine to ebola

0 · Reply

csabuus Aug. 18 at 7:17 PM

$SNGX lwts go to 1

0 · Reply

DrLotto Aug. 18 at 7:15 PM

$SNGX Guys, if CEPI approves ThermoVax, which price can it hit? Any suggestions?

2 · Reply

JK1033 Aug. 18 at 5:21 PM

$SNGX Typical Review Window: Major global health agencies like the Coalition for Epidemic Preparedness Innovations (CEPI) and BARDA typically run a multi-stage review process that takes 3 to 6 months from application to formal public announcement.SNGX Estimated Catalyst Date: Because Soligenix formally submitted its vaccine development funding application for the Bundibugyo Ebola vaccine program in June 2026, a decision or update from CEPI is highly anticipated between September 2026 and December 2026.

1 · Reply

JK1033 Aug. 18 at 5:20 PM

$SNGX Soligenix is locked in a tight race against time. The December 7, 2026 Nasdaq compliance deadline sits right at the end of the expected window for their CEPI grant decision.If CEPI approves the grant before December, a massive spike in positive sentiment could push SNGX organically over $1.00, rendering a split unnecessary. If the decision is delayed or rejected, a sixth historical reverse stock split is highly probable before the year ends to prevent delisting

0 · Reply

DrLotto Aug. 18 at 10:28 AM

$SNGX 0.46-0.5 + Today

1 · Reply

UWanSum Aug. 18 at 10:09 AM

$SNGX this thing finally waking up?

0 · Reply

DrLotto Aug. 18 at 10:06 AM

$SNGX market cap only 8m.

0 · Reply

Market Cap	6.00M
Revenue (ttm)	0.00
Net Income (ttm)	-11.08M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	590,856
Avg Vol	413,004
Day's Range	N/A - N/A
Shares Out	14.82M
Stochastic %K	61%
Beta	1.93
Analysts	Strong Buy
Price Target	$1.38